{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:59:39Z","timestamp":1793735979827,"version":"4.6.1"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Secondary brain injuries, including delayed cerebral ischemia, neuroinflammation, and stroke induced cerebral edema can occur following both ischemic and hemorrhagic strokes, contributing to a negative impact on clinical outcomes. Glibenclamide, a sulfonylurea antidiabetic medication, has shown potential in minimizing these consequences by targeting the SUR1-TRPM4 channel. However, glibenclamide\u2019s therapeutic effectiveness and safety in stroke patients remain unknown. Therefore, this systematic review aims to assess the safety and efficacy of glibenclamide in improving outcomes following both ischemic and hemorrhagic strokes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Four databases were searched for RCTs published up to November 2024. Studies were included if they involved adult patients with ischemic stroke, hemorrhagic stroke, or subarachnoid hemorrhage, and reported relevant safety and efficacy outcomes. Efficacy outcomes were measured using the Modified Rankin Scale at 3 and 6\u202fmonths. Safety outcomes included adverse events such as hypoglycemia, hydrocephalus, and mortality.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Data from six RCTs, involving 555 patients (280 intervention, 275 control), were included: 4 trials in subarachnoid hemorrhage, one trial in ischemic stroke, and one in hemorrhagic stroke. At 3\u202fmonths, the pooled odds ratio (OR) for poor functional outcomes was 0.98 (95% CI: 0.65\u20131.48), and at 6\u202fmonths, 0.52 (95% CI: 0.24\u20131.12; <jats:italic>p<\/jats:italic>\u202f=\u202f0.094), with no significant differences between glibenclamide and placebo. Safety analysis showed a significant increase in symptomatic hypoglycemia (OR 4.69, 95% CI: 1.45\u201315.23; <jats:italic>p<\/jats:italic>\u202f=\u202f0.010) but no significant differences for hydrocephalus (OR 1.60, 95% CI: 0.76\u20133.37; <jats:italic>p<\/jats:italic>\u202f=\u202f0.220) or mortality (OR 0.57, 95% CI: 0.32\u20131.05; <jats:italic>p<\/jats:italic>\u202f=\u202f0.071). Delayed cerebral ischemia (DCI) showed a borderline reduction in risk (OR 0.43, 95% CI: 0.18\u20131.00; <jats:italic>p<\/jats:italic>\u202f=\u202f0.051) in the treatment group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In patients with ischemic or hemorrhagic stroke, glibenclamide demonstrates a favorable safety profile but shows limited efficacy in improving functional outcomes. The elevated risk of hypoglycemia emphasizes the necessity of using this medication with caution.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2025.1609101","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T08:28:31Z","timestamp":1751012911000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Safety and efficacy of glibenclamide on functional outcomes in ischemic and hemorrhagic stroke: a systematic review and meta-analysis of randomized clinical trials"],"prefix":"10.3389","volume":"16","author":[{"given":"Ola Bin","family":"Shilash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussam","family":"Alhathlol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Alduhaysh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan","family":"Almufarriji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Bafaquh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"e072385","DOI":"10.1136\/bmj-2022-072385","article-title":"Global burden of type 2 diabetes in adolescents and young adults, 1990\u20132019: systematic analysis of the Global Burden of Disease Study 2019","volume":"379","author":"Xie","year":"2022","journal-title":"BMJ"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1016\/S0140-6736(08)60694-7","article-title":"Stroke","volume":"371","author":"Donnan","year":"2008","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/S1474-4422(16)30196-X","article-title":"Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"15","author":"Sheth","year":"2016","journal-title":"Lancet Neurol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s12028-024-01999-z","article-title":"Efficacy and safety of early treatment with glibenclamide in patients with aneurysmal subarachnoid hemorrhage: a randomized controlled trial","volume":"41","author":"Lin","year":"2024","journal-title":"Neurocrit Care"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1161\/STROKEAHA.110.595090","article-title":"Neuroprotection in subarachnoid hemorrhage","volume":"41","author":"Laskowitz","year":"2010","journal-title":"Stroke"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/jcbfm.2012.166","article-title":"Glibenclamide enhances neurogenesis and improves long-term functional recovery after transient focal cerebral ischemia","volume":"33","author":"Ortega","year":"2013","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/svn-2023-002892","article-title":"Safety and efficacy of glibenclamide on cerebral oedema following aneurysmal subarachnoid haemorrhage: a randomised, double-blind, placebo-controlled clinical trial","volume":"9","author":"Feng","year":"2024","journal-title":"Stroke Vasc Neurol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3171\/2021.7.JNS21846","article-title":"Glibenclamide in aneurysmal subarachnoid hemorrhage: a randomized controlled clinical trial","volume":"137","author":"da Costa","year":"2022","journal-title":"J Neurosurg"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"101666","DOI":"10.1016\/j.eclinm.2022.101666","article-title":"Efficacy and safety of glibenclamide therapy after intracerebral haemorrhage (GATE-ICH): a multicentre, prospective, randomised, controlled, open-label, blinded-endpoint, phase 2 clinical trial","volume":"53","author":"Zhao","year":"2022","journal-title":"EClinicalMedicine"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.wneu.2024.09.048","article-title":"The effects of glibenclamide on cognitive performance, quality of life, and emotional aspects among patients with aneurysmal subarachnoid hemorrhage: a randomized controlled trial","volume":"193","author":"Windlin","year":"2024","journal-title":"World Neurosurg"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1161\/STROKEAHA.117.020365","article-title":"Long-term outcomes in patients aged \u226570 years with intravenous glyburide from the phase II GAMES-RP study of large hemispheric infarction an exploratory analysis","volume":"49","author":"Sheth","year":"2018","journal-title":"Stroke"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.hest.2024.07.006","article-title":"Effects of glibenclamide\/glyburide on stroke: systematic review","volume":"5","author":"dos Santos","year":"2024","journal-title":"Brain Hemorrh"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"134729","DOI":"10.1016\/j.neulet.2019.134729","article-title":"SUR1-TRPM4 channels, not KATP, mediate brain swelling following cerebral ischemia","volume":"718","author":"Woo","year":"2020","journal-title":"Neurosci Lett"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.3390\/ijms16034973","article-title":"Glibenclamide for the treatment of ischemic and hemorrhagic stroke","volume":"16","author":"Caffes","year":"2015","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1609101\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T08:28:32Z","timestamp":1751012912000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1609101\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,27]]},"references-count":15,"alternative-id":["10.3389\/fneur.2025.1609101"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1609101","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,27]]},"article-number":"1609101"}}